Streetbeat News

Products Services

PRFX

PainReform Ltd. has confirmed the optimal delivery method for its product PRF-110 in bunionectomy procedures, highlighting its superior coverage and stability in surgical wounds. This positions PRF-110 as a competitive post-surgical pain management solution.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 12:34 pm

RIO

XCMG Machinery has signed a significant global cooperation agreement with Rio Tinto for the Simandou iron ore project in Guinea. The deal involves supplying over $110 million in core mining equipment, including 34 mining trucks and large graders.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 12:34 pm

SABR

Sabre Corporation has finalized a renewal of its distribution agreement with Delta Air Lines, ensuring continued collaboration in providing travel solutions. This agreement is significant for Sabre as it maintains its relationship with a major airline, potentially impacting its market position positively.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 12:33 pm

ICCT

iCoreConnect has entered into a channel partner agreement with DSO MarketWatch to improve business intelligence solutions for over 2,700 dental support organizations and 150,000 solo practicing dentists.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 12:32 pm

IVDA

Iveda has integrated its IvedaCare and IvedaAI solutions at Waymark Gardens, a senior living facility in Arizona, to enhance safety and operational efficiency. This integration supports Iveda's subcontract under a $1.032 billion VA contract for remote patient monitoring.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 12:32 pm

ATOS

Atossa Therapeutics, in collaboration with Quantum Leap Healthcare Collaborative, has dosed the first patient in a clinical trial evaluating (Z)-Endoxifen with Abemaciclib as a neoadjuvant treatment for high-risk ER+/HER2- breast cancer.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 12:30 pm

OGEN

Oragenics Inc. (NYSE:OGEN) has completed the manufacturing of its spray-dried drug formulation and intranasal device filling for ONP-002, a treatment for concussions. The company is preparing for a Phase 2a clinical trial in Australia, aiming to enroll 40 patients. The trial will assess the drug's efficacy in reducing negative outcomes after a concussion.

Portfolio Pulse from Vandana Singh

August 21, 2024 | 12:30 pm

OGEN

Oragenics has announced that its drug, ONP-002, could potentially be the first pharmaceutical treatment available for concussions. Currently, there are no pharmaceutical treatments for concussions, highlighting the significance of this development.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 12:30 pm

OGEN

Oragenics has completed the spray dry drug manufacturing and intranasal device filling in preparation for a Phase IIa clinical trial targeting concussed patients.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 12:30 pm

BA

GCAD

ITA

Boeing's 777X jetliner faces delays due to structural cracks found during test flights, potentially pushing the launch to 2026. This adds to Boeing's ongoing challenges, including FAA inspections and regulatory issues. Boeing shares are slightly up premarket.

Portfolio Pulse from Lekha Gupta

August 21, 2024 | 12:16 pm